SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2768)9/11/2012 11:46:14 PM
From: scaram(o)uche  Respond to of 3202
 
Interesting change to this 110 protocol......

clinicaltrials.gov

Implies that tolerability looks good, or that efficacy is marginal?

;-)

Molecule is flying.



To: scaram(o)uche who wrote (2768)11/1/2012 3:17:51 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 3202
 
They still won't verify that 110 is jak1-specific. "Joint" (INCY and Lilly?) analyst meeting at ACR, 11/13. ASH abstracts expected out Monday, with survival-relevant stuff.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News